Nonetheless, the SPHK2-I used in this study may also represent a drug of interest in the treatment of aggressive mastocytosis since it is already in clinical trials for other malignancies and as demonstrated here, is also quite effective in reducing the numbers of CD25+ MCs and other neoplastic MCs. This evidence concerns the gene IL2RA and mastocytosis.